Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Neuroimmunol. 2013 May 15;258(1-2):61-6. doi: 10.1016/j.jneuroim.2013.03.001. Epub 2013 Apr 3.

Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis.

Author information

  • 1Department of Neurology, Keio University School of Medicine, Tokyo, Japan. sgsuzuki@z3.keio.jp


There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

Copyright © 2013 Elsevier B.V. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk